Cognetivity Neurosciences Ltd.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Cognetivity Neurosciences Ltd. Cognetivity Neurosciences Ltd. (CGNSF) is a medical technology company that develops artificial intelligence-powered platforms for the early detection of cognitive impairment, dementia, and Alzheimer's disease. The company offers its flagship Integrated Cognitive Assessment (ICA), a patented five-minute touchscreen and web-based cognitive testing platform that employs machine learning to analyze brain performance across multiple domains for rapid, scalable diagnosis in clinical settings; OptiMind, a consumer wellness app for brain health monitoring; and related software-as-a-medical-device (SaMD) solutions for neurological assessment and biomarker estimation. These products serve healthcare providers, elder care facilities, research institutions, and corporate wellness programs, with deployments targeting primary and secondary care environments. Cognetivity Neurosciences operates primarily in North America, Europe, and the Middle East, with customers including South London and Maudsley NHS Foundation Trust, Emirates Health Services, Dubai Health Authority, Clemenceau Medical Centre, PRIME Health, and Ketamine One Capital Ltd. The company, founded in 2013 (originally incorporated in 2015 as Utor Capital Corp., with a name change in December 2017), maintains its headquarters in Vancouver, British Columbia, Canada, and a key development presence linked to the University of Cambridge, UK. In recent developments, Cognetivity Neurosciences completed a funding round with strategic investor SAYACORP to support platform commercialization as of 2025. The company expanded through commercial agreements, including a 2022 contract with PRIME Health for ICA brain health screenings across UAE facilities, a 2021 partnership with Ketamine One Capital Ltd. for North American clinic deployments, and a May 2021 alliance with InterSystems for electronic health record integration to enhance adoption in global healthcare systems. These initiatives reflect ongoing efforts to scale ICA in medical and commercial markets amid a projected $11.4 billion cognitive assessment sector by 2026.
CSE Bulletin: Delist - Cognetivity Neurosciences Ltd. (CGN)
CognICA(TM) Shown to Save Tens of Millions of Dollars in Healthcare Costs Annually and Improve Patient Outcomes in the UK National Health Service
Cognetivity Neurosciences and UC Health Partner to Improve Early Detection of Cognitive Impairment in USA
Cognetivity Neurosciences Announces Commercial Agreement with Mediclinic to Provide Cognitive Assessment to Over 50s
Cognetivity Neurosciences Partners with No Fear Counselling to Pioneer Brain Health Assessment Through Groundbreaking AI Technology
Cognetivity Neurosciences' AI Powered CognICA Platform Wins Major Industry Award
Cognetivity Neurosciences' AI Powered CognICA Platform Shortlisted for Major Industry Award
Cognetivity Neurosciences Announces Publication of Peer-Reviewed Article Showing Effectiveness of its AI Powered CognICA Technology in Detecting Early-Stage Alzheimer's Disease
Cognetivity Neurosciences Announces Successful Registration With Health Canada for Clinical use of CognICA(TM) AI-Powered Brain Health Technology in Canada
New Disease Modifying Drug for Alzheimer's Disease Fully Approved by FDA, Highlighting the Crucial Role for Cognetivity in Early Detection and Monitoring
Eli Lilly Releases Positive Results on Latest Disease Modifying Therapeutic for Alzheimer's Disease, Highlighting Need for Cognetivity's CognICA Platform